Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 4:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 2,738 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Tumors, Neuroendocrine Clear all
Recruiting Phase 1 Interventional

Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.

NCT07150546
View directory record Official record
Conditions
Digestive System Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Digestive System Neuroendocrine Tumor G2
Interventions
Stereotactic Body Radiation Therapy, Lutetium Lu 177 Dotatate, Computed Tomography, Magnetic Resonance Imaging, Gallium Ga 68-DOTATATE, Positron Emission Tomography, Questionnaire Administration
Radiation · Drug · Procedure + 1 more
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 16, 2026, 4:43 AM EDT
Completed Phase 2 Interventional Results available

Survivorship Promotion In Reducing IGF-1 Trial

NCT02431676
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer, Melanoma of Skin, Endometrial Cancer, Liver Cancer, Pancreatic Cancer, Rectal Cancer, Kidney Cancer, Other Solid Malignant Tumors
Interventions
Metformin, Coach Directed Behavioral Weight Loss, Self-control weight loss
Drug · Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 16, 2026, 4:43 AM EDT
Completed Phase 1 Interventional

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

NCT01176474
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
NY-ESO-1 157-165 (165V), Nivolumab, gp100:280-288 (288V), Montanide ISA 51 vegetable grade (VG), Ipilimumab, Apheresis Procedure
Biological · Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
16 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 16, 2026, 4:43 AM EDT
Completed Phase 1 Interventional Results available

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

NCT01211262
View directory record Official record
Conditions
Malignant Melanoma
Interventions
IMCgp100
Drug
Lead sponsor
Immunocore Ltd
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
4
States / cities
Los Angeles, California • New Haven, Connecticut • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 16, 2026, 4:43 AM EDT
Completed Phase 1 Interventional

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

NCT03289962
View directory record Official record
Conditions
Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Renal Cancer, Head and Neck Cancer, Other Solid Cancers
Interventions
Autogene cevumeran, Atezolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
15
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 16, 2026, 4:43 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

NCT07749586
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
ARV-6723, Pembrolizumab, SOC
Drug
Lead sponsor
Arvinas Inc.
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
New York, New York • Huntersville, North Carolina • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 16, 2026, 4:43 AM EDT
Completed Phase 2 Interventional

Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma

NCT00938223
View directory record Official record
Conditions
Melanoma
Interventions
4-peptide and 12-peptide melanoma vaccines
Biological
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years to 85 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 16, 2026, 4:43 AM EDT
Withdrawn Phase 2 Interventional

Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00085579
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
aldesleukin, sargramostim, adjuvant therapy
Biological · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2012 · Synced Oct 16, 2026, 4:43 AM EDT
Completed Phase 1Phase 2 Interventional

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

NCT04305054
View directory record Official record
Conditions
Melanoma
Interventions
Pembrolizumab, Vibostolimab, Pembrolizumab/Quavonlimab, Lenvatinib, Favezelimab/Pembrolizumab, ATRA
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
15
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 16, 2026, 4:43 AM EDT
Terminated Phase 1 Interventional

TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors

NCT02650635
View directory record Official record
Conditions
Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Melanoma of the Skin, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Renal Cell Carcinoma, Solid Neoplasm, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IVA Colorectal Cancer, Stage IVA Pancreatic Cancer, Stage IVB Colorectal Cancer, Stage IVB Pancreatic Cancer
Interventions
Cyclophosphamide, Laboratory Biomarker Analysis, Pegfilgrastim, Pharmacological Study, TLR8 Agonist VTX-2337
Drug · Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 16, 2026, 4:43 AM EDT
Completed Phase 2 Interventional Results available

Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors

NCT02259725
View directory record Official record
Conditions
Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Pancreatic Polypeptide Tumor, Pulmonary Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Somatostatinoma
Interventions
regorafenib, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
5
States / cities
Scottsdale, Arizona • Los Angeles, California • Newport Beach, California + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 16, 2026, 4:43 AM EDT
Completed Phase 1 Interventional

A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers

NCT00926640
View directory record Official record
Conditions
Carcinoma Neuroendocrine, Small Cell Lung Carcinoma, Malignant Epithelial Neoplasms
Interventions
Belinostat, Cisplatin, Etoposide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 16, 2026, 4:43 AM EDT
Completed Phase 2 Interventional Results available

Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

NCT04552223
View directory record Official record
Conditions
Metastatic Uveal Melanoma
Interventions
Nivolumab, Relatlimab
Drug
Lead sponsor
Jose Lutzky, MD
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 16, 2026, 4:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Optical Biopsy of Human Skin in Conjunction With Laser Treatment

NCT00540566
View directory record Official record
Conditions
Malignant Melanoma, Merkel Cell Carcinoma, Basal Cell Carcinoma, Squamous Cell Carcinoma, Atypical Nevi, Congenital Nevi, Seborrheic Keratosis, Paget's Disease, Dermatofibroma, Kaposi's Sarcoma, Port Wine Stain, Hemangioma, Tattoos, Scleroderma, Burns
Interventions
Optical Biopsy imaging
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 75 Years
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2008
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 16, 2026, 4:43 AM EDT
Suspended Phase 1 Interventional

Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma

NCT01083966
View directory record Official record
Conditions
Vestibular Schwannoma
Interventions
Bevacizumab (Avastin)
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 16, 2026, 4:43 AM EDT
Not listed Phase 1 Interventional

Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors

NCT05266612
View directory record Official record
Conditions
Solid Tumor
Interventions
VG2025, Nivolumab Injection [Opdivo]
Drug
Lead sponsor
Virogin Biotech Canada Ltd
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Gilbert, Arizona • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 16, 2026, 4:43 AM EDT
Completed Phase 3 Interventional Results available

Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)

NCT03783078
View directory record Official record
Conditions
Merkel Cell Carcinoma
Interventions
Pembrolizumab (MK-3475)
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
12 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 16, 2026, 4:43 AM EDT
Terminated No phase listed Observational

Sample Collection From Melanoma Patients

NCT00507325
View directory record Official record
Conditions
Melanoma
Interventions
Blood Sample, Tumor Sample
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Oct 16, 2026, 4:43 AM EDT
Completed Not applicable Interventional

Neurotropic Melanoma of the Head and Neck

NCT00975520
View directory record Official record
Conditions
Melanoma
Interventions
Observation, Radiation Therapy
Other · Radiation
Lead sponsor
Melanoma and Skin Cancer Trials Limited
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 16, 2026, 4:43 AM EDT
Completed Phase 2 Interventional

In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®

NCT02423863
View directory record Official record
Conditions
Melanoma, Head and Neck Cancer, Sarcoma, Non-Melanoma Skin Cancers
Interventions
Hiltonol
Biological
Lead sponsor
Oncovir, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
5
States / cities
Chevy Chase, Maryland • Easton, Maryland • Columbia, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 16, 2026, 4:43 AM EDT
Withdrawn Not applicable Interventional

Pancreatic Cancer Screening of High-Risk Individuals in Arkansas

NCT02309632
View directory record Official record
Conditions
Pancreatic Neoplasms, Peutz-Jegher's Syndrome, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ataxia Telangiectasia, Familial Atypical Mole-Malignant Melanoma Syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Hereditary Pancreatitis
Interventions
Pancreatic Cancer Screening Pathway 1, Pancreatic Cancer Screening Pathway 2
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 16, 2026, 4:43 AM EDT
Completed No phase listed Observational

Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma

NCT00617799
View directory record Official record
Conditions
Kidney Cancer, Melanoma (Skin)
Interventions
aldesleukin, gene expression analysis, mutation analysis, flow cytometry
Biological · Genetic · Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 16, 2026, 4:43 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma

NCT04589832
View directory record Official record
Conditions
Uveal Melanoma
Interventions
PAC-1, Entrectinib
Drug
Lead sponsor
Arkadiusz Z. Dudek, MD
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 16, 2026, 4:43 AM EDT
Completed Phase 2 Interventional Results available

Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye

NCT01413191
View directory record Official record
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma, Stage IV Intraocular Melanoma
Interventions
Cixutumumab, Laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
17 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 16, 2026, 4:43 AM EDT